Mazdutide 5mg Dosage & Mixing Guide

What is Mazdutide?

Mazdutide (also known as IBI362 or LY3305677) is a GLP-1 receptor and glucagon receptor dual agonist, an oxyntomodulin analog developed by Eli Lilly and Innovent Biologics for research into obesity and metabolic disorders.

The peptide works by co-activating two distinct receptor systems. Through GLP-1 receptor agonism it influences appetite suppression, glucose-dependent insulin secretion, and slowed gastric emptying. Through glucagon receptor agonism it promotes increased energy expenditure and hepatic lipid metabolism. This dual mechanism acts on both food intake and metabolic rate simultaneously.

Mazdutide has an extended half-life suitable for once-weekly administration in research protocols. It is a research peptide and not an approved medicine.

Quick Reference

Reconstitution Guide

Materials Needed

• Mazdutide 5mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (U-100, 29-31 gauge)
• Alcohol swabs
• Sharps container

Step-by-Step Instructions

1. Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.

2. Clean the vial stoppers — Wipe the Mazdutide vial stopper and BAC water vial with alcohol swabs. Allow to dry completely.

3. Draw the BAC water — Using a sterile syringe, draw 2mL of bacteriostatic water.

4. Add water to peptide vial — Insert the needle into the Mazdutide vial and slowly inject the BAC water down the inside wall of the vial. Do not spray directly onto the powder.

5. Allow to dissolve — Mazdutide may take 5-10 minutes to fully dissolve. Gently swirl occasionally — never shake vigorously.

6. Verify dissolution — The solution should be completely clear and colorless. If cloudy or particles remain, continue gentle swirling.

7. Label and store — Write the reconstitution date on the vial. Store in refrigerator immediately.

Dosage Protocol

Concentration Calculations

With 5mg peptide in 2mL BAC water:

• Concentration: 2.5mg/mL = 2500mcg/mL
• Per unit (U-100 syringe): 25mcg per unit

Common Dose Calculations

Note: Higher mazdutide doses exceed the volume of a single U-100 syringe and require multiple draws. A more concentrated 10mg vial reduces the draw volume per dose.

Suggested Titration Protocol

Mazdutide research protocols employ gradual dose escalation to assess tolerance, as the dual GLP-1/glucagon mechanism reaches higher effective doses than single GLP-1 agonists:

Important Notes:

• Each dose level should be maintained for at least 4 weeks before escalation
• Not all research protocols require reaching maximum dose
• Dose escalation should be based on research objectives and tolerance

Injection Guide

Subcutaneous Administration

1. Clean the injection site with an alcohol swab
2. Pinch a fold of skin (abdomen, thigh, or upper arm)
3. Insert needle at 90° angle for most body types
4. Inject slowly and steadily
5. Wait 5-10 seconds before withdrawing needle
6. Apply light pressure if needed — do not rub

Site Rotation

Rotate between these areas weekly:

• Abdomen (2+ inches from navel) — most common
• Outer thigh (front/outer area)
• Back of upper arm

Consistency tip: Administer on the same day each week to maintain steady levels.

Storage Requirements

Lyophilized (Powder Form)

• Temperature: -20°C (-4°F) or colder
• Duration: 2+ years
• Conditions: Protect from light and moisture

Reconstituted (Mixed with BAC Water)

• Temperature: 2-8°C (36-46°F) — standard refrigerator
• Duration: 4-6 weeks
• Conditions: Keep away from light, never freeze reconstituted solution

Important Storage Notes

• Mazdutide is sensitive to temperature — minimize time outside refrigeration
• Do not use if solution becomes cloudy, discolored, or contains particles
• Keep track of reconstitution date and discard after 6 weeks maximum

Research Considerations

Mechanism of Action

Mazdutide’s research applications stem from its dual GLP-1 and glucagon receptor agonism:

• GLP-1 receptor effects: Appetite suppression, glucose-dependent insulin secretion, slowed gastric emptying
• Glucagon receptor effects: Increased energy expenditure, hepatic lipid metabolism
• Combined effect: Simultaneous action on food intake and metabolic rate
• Metabolic: Observed effects on body weight and hepatic fat in research settings

Key Research Findings

Clinical research on mazdutide (IBI362) has demonstrated:

• Significant effects on body weight in participants with overweight or obesity
• Dose-dependent responses across the 3mg to 9mg weekly range
• Metabolic parameter changes consistent with the dual-agonist mechanism

Safety & Handling

General Precautions

• Use sterile technique for all preparations
• Never reuse needles or syringes
• Dispose of sharps properly in designated containers
• Store away from children and unauthorized persons

Research Considerations

• Mazdutide is for research purposes only
• Mazdutide is an investigational compound and is not an approved medicine
• Research-grade peptides are not equivalent to pharmaceutical preparations
• Follow institutional guidelines for peptide research

Sourcing for Research

Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.

Scientific References

1. Ji L, et al. “Efficacy and safety of mazdutide in Chinese participants with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 2 trial.” 2024.
2. Innovent Biologics / Eli Lilly mazdutide (IBI362) clinical development program, GLP-1/glucagon dual agonist studies.

Last updated: July 04, 2026

Disclaimer: This information is for educational and research purposes only. Mazdutide as a research peptide is not intended for human consumption. Mazdutide is an investigational compound and is not an approved medicine. Always follow applicable laws and institutional guidelines.